AU2022207648A9
(en )
2025-03-13
Isoindolinone compounds
CA3261302A1
(en )
2024-02-22
Heterocycle rbm39 modulators
EP4241773A4
(en )
2024-10-16
Pharmaceutical composition for treating leukemia comprising flt3 inhibitor
AU2024246994A1
(en )
2025-11-13
Methods for reducing exogenous insulin use
HK40112940A
(en )
2025-01-28
Covalent inhibitors of menin-mll interaction for diabetes mellitus
CA3263420A1
(en )
2024-02-01
Fto inhibitors
CA3265189A1
(en )
2024-02-22
Inhibitors of myeloperoxidase
EP4144734A4
(en )
2023-11-01
Application of heterocyclic compound
HK40103863A
(en )
2024-07-12
Isoindolinone compounds
CA3289111A1
(en )
2024-10-31
Treatment of diabetes mellitus
CA3270489A1
(en )
2024-04-18
Compounds for use as medicaments
CA3260086A1
(en )
2025-10-30
Compounds as myt1 inhibitors
HK40107059A
(en )
2024-10-04
Certain fascin binding compounds for spinogenesis
CA3280853A1
(en )
2024-08-29
Inhibitors of synaptogyrin-3 expression
HK40118483A
(en )
2025-06-20
Heterocyclic compounds as pi3ka inhibitors
CA3279320A1
(en )
2024-07-18
Compounds for fgfrs inhibitors
HK40104116A
(en )
2024-07-19
Biosensor for determination of hemoglobin
HK40098679A
(en )
2024-04-05
Substrate for single molecule organization
HK40123415A
(en )
2025-10-17
Heterocyclic compounds capable of activating sting
CA3270840A1
(en )
2024-05-02
Heterocyclic compounds capable of activating sting
CA3266173A1
(en )
2024-05-02
Heterocyclic compounds capable of activating sting
HK40111748A
(en )
2025-01-03
Use of heterocyclic compound
HK40092814A
(en )
2023-12-29
Methods of treating diabetes
CA3280714A1
(en )
2024-08-02
Substituted 1h-pyrazole-4-carboxamides as sarm1 inhibitors
AU2024298839A1
(en )
2025-01-30
Pharmaceutical composition containing heterocyclic compound